A Comprehensive View of Nuclear Receptor Cancer Cistromes

被引:111
|
作者
Tang, Qianzi [1 ]
Chen, Yiwen [2 ]
Meyer, Clifford [2 ]
Geistlinger, Tim [3 ]
Lupien, Mathieu
Wang, Qian [1 ]
Liu, Tao [2 ]
Zhang, Yong [1 ]
Brown, Myles [3 ]
Liu, Xiaole Shirley [2 ]
机构
[1] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
关键词
MODEL-BASED ANALYSIS; BREAST-CANCER; ANDROGEN RECEPTOR; LIPID-METABOLISM; PROSTATE-CANCER; CHIP-CHIP; INFLAMMATION; ACTIVATION; SIGNATURE; REVEALS;
D O I
10.1158/0008-5472.CAN-11-2091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear receptors comprise a superfamily of ligand-activated transcription factors that play important roles in both physiology and diseases including cancer. The technologies of chromatin immunoprecipitation followed by array hybridization (ChIP-chip) or massively parallel sequencing (ChIP-seq) has been used to map, at an unprecedented rate, the in vivo genome-wide binding (cistrome) of nuclear receptors in both normal and cancer cells. We developed a curated database of 88 nuclear receptor cistrome data sets and other associated high-throughput data sets including 121 collaborating factor cistromes, 94 epigenomes, and 319 transcriptomes. Through integrative analysis of the curated nuclear receptor ChIP-chip/seq data sets, we discovered novel factor-specific noncanonical motifs that may have important regulatory roles. We also revealed a common feature of nuclear receptor pioneering factors to recognize relatively short and AT-rich motifs. Most nuclear receptors bind predominantly to introns and distal intergenetic regions, and binding sites closer to transcription start sites were found to be neither stronger nor more evolutionarily conserved. Interestingly, while most nuclear receptors appear to be predominantly transcriptional activators, our analysis suggests that the binding of ESR1, RARA, and RARG has both activating and repressive effects. Through meta-analysis of different omic data of the same cancer cell line model from multiple studies, we generated consensus cistrome and expression profiles. We further made probabilistic predictions of the nuclear receptor target genes by integrating cistrome and transcriptome data and validated the predictions using expression data from tumor samples. The final database, with comprehensive cistrome, epigenome, and transcriptome data sets and downstream analysis results, constitutes a valuable resource for the nuclear receptor and cancer community. Cancer Res; 71(22); 6940-7. (C)2011 AACR.
引用
收藏
页码:6940 / 6947
页数:8
相关论文
共 50 条
  • [21] Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer
    Porter, Baylee A.
    Ortiz, Maria A.
    Bratslavsky, Gennady
    Kotula, Leszek
    CANCERS, 2019, 11 (12)
  • [22] Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer
    Llopis, Shawn
    Singleton, Brittany
    Duplessis, Tamika
    Carrier, Latonya
    Rowan, Brian
    Williams, Christopher
    BMC CANCER, 2013, 13
  • [23] A Comprehensive View of the β-Arrestinome
    Crepieux, Pascale
    Poupon, Anne
    Langonne-Gallay, Nathalie
    Reiter, Eric
    Delgado, Javier
    Schaefer, Martin H.
    Bourquard, Thomas
    Serrano, Luis
    Kiel, Christina
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [24] Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
    Lopez, Sandra M.
    Agoulnik, Alexander I.
    Zhang, Manqi
    Peterson, Leif E.
    Suarez, Egla
    Gandarillas, Gregory A.
    Frolov, Anna
    Li, Rile
    Rajapakshe, Kimal
    Coarfa, Christian
    Ittmann, Michael M.
    Weigel, Nancy L.
    Agoulnik, Irina U.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3937 - 3949
  • [25] A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer
    Eggermont, Lissa
    Lumen, Nicolaas
    Van Praet, Charles
    Delanghe, Joris
    Rottey, Sylvie
    Vermassen, Tijl
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2025, 1880 (01):
  • [26] Cancer Stem Cells and Androgen Receptor Signaling: Partners in Disease Progression
    Quintero, Juan Carlos
    Diaz, Nestor Fabian
    Rodriguez-Dorantes, Mauricio
    Camacho-Arroyo, Ignacio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [27] Nuclear Receptor Coregulators in Hormone-Dependent Cancers
    Jafari, Hedieh
    Hussain, Shahid
    Campbell, Moray J.
    CANCERS, 2022, 14 (10)
  • [28] The Role of Nuclear Receptors in Prostate Cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Kashiwagi, Eiji
    Eto, Masatoshi
    CELLS, 2019, 8 (06)
  • [29] Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine
    De Mattia, Elena
    Cecchin, Erika
    Roncato, Rossana
    Toffoli, Giuseppe
    PHARMACOGENOMICS, 2016, 17 (14) : 1547 - 1571
  • [30] Research Resource: Diagnostic and Therapeutic Potential of Nuclear Receptor Expression in Lung Cancer
    Jeong, Yangsik
    Xie, Yang
    Lee, Woochang
    Bookout, Angie L.
    Girard, Luc
    Raso, Gabriela
    Behrens, Carmen
    Wistuba, Ignacio I.
    Gadzar, Adi F.
    Minna, John D.
    Mangelsdorf, David J.
    MOLECULAR ENDOCRINOLOGY, 2012, 26 (08) : 1443 - 1454